237 related articles for article (PubMed ID: 15551131)
1. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.
Wild D; Mäcke HR; Waser B; Reubi JC; Ginj M; Rasch H; Müller-Brand J; Hofmann M
Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):724. PubMed ID: 15551131
[No Abstract] [Full Text] [Related]
2. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
4. Metastatic neuroendocrine carcinoma presenting as a "Superscan" on 68Ga-DOTANOC somatostatin receptor PET/CT.
Naswa N; Karunanithi S; Soundararajan R; Das KJ; Agarwal KK; Malhotra A; Bal C; Kumar R
Clin Nucl Med; 2012 Sep; 37(9):892-4. PubMed ID: 22889781
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTANOC somatostatin receptor PET-CT imaging in multiple myeloma.
Sharma P; Dhull VS; Suman S; Bal C; Malhotra A; Kumar R
Clin Nucl Med; 2014 Apr; 39(4):374-5. PubMed ID: 23640227
[TBL] [Abstract][Full Text] [Related]
6. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging.
Ambrosini V; Nanni C; Fanti S
PET Clin; 2014 Jul; 9(3):323-9. PubMed ID: 25030395
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor PET imaging with Gallium-68 labeled peptides.
Win Z; Al-Nahhas A; Rubello D; Gross MD
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):244-50. PubMed ID: 17464267
[TBL] [Abstract][Full Text] [Related]
9. What can gallium-68 PET add to receptor and molecular imaging?
Al-Nahhas A; Win Z; Szyszko T; Singh A; Khan S; Rubello D
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1897-901. PubMed ID: 17713764
[No Abstract] [Full Text] [Related]
10. 68Ga DOTANOC PET/CT for accurate delineation of disease extent in a case of sinonasal small cell neuroendocrine carcinoma.
Singhal A; Singla S; Sharma P; Dhull VS; Khangembam BC; Kumar R
Clin Nucl Med; 2013 Oct; 38(10):e395-6. PubMed ID: 23603589
[TBL] [Abstract][Full Text] [Related]
11. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?
Basu S; Ostwal V
Nucl Med Commun; 2016 Jun; 37(6):669-71. PubMed ID: 27105440
[No Abstract] [Full Text] [Related]
12. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
13. Gallium-68 PET: a new frontier in receptor cancer imaging.
Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D
Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
Ambrosini V; Campana D; Bodei L; Nanni C; Castellucci P; Allegri V; Montini GC; Tomassetti P; Paganelli G; Fanti S
J Nucl Med; 2010 May; 51(5):669-73. PubMed ID: 20395323
[TBL] [Abstract][Full Text] [Related]
15. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
Johnbeck CB; Knigge U; Kjær A
Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTANOC PET/CT in Adrenal Schwannoma.
Aggarwal P; Singh H; Kumar R; Nada R; Bora GS; Walia R
Clin Nucl Med; 2023 Jan; 48(1):e22-e23. PubMed ID: 36469076
[TBL] [Abstract][Full Text] [Related]
17. Nuclear medicine imaging of neuroendocrine tumours.
Al-Nahhas A
Clin Med (Lond); 2012 Aug; 12(4):377-80. PubMed ID: 22930887
[No Abstract] [Full Text] [Related]
18. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
19. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):91-7. PubMed ID: 25029938
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-DOTANOC PET-CT demonstrating in vivo somatostatin receptor expression in idiopathic gynecomastia.
Dhull VS; Sharma P; Singla S; Singhal A; Bal C; Kumar R
Clin Nucl Med; 2013 Aug; 38(8):e324-5. PubMed ID: 23531768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
